Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients With With Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Sponsor: Ali Rezai
This EARLY_PHASE1 trial investigates Alzheimer Disease 1 and Mild Cognitive Impairment and is currently ongoing. Ali Rezai leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting EARLY_PHASE1
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Oct 2025 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Recruiting EARLY_PHASE1
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2024 — Mar 2024 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2022 — Jan 2024 [monthly]
Recruiting EARLY_PHASE1
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ali Rezai
- InSightec
For direct contact, visit the study record on ClinicalTrials.gov .